Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Candidiasis
CombinatorX Announces Top-Line Results from Phase 2b Study of Synavive (CRx-102) for Knee Osteoarthritis
October 25th, 2008
CombinatoRx, Incorporated (NASDAQ: CRXX), announced preliminary top-line results from COMET-1 (CRx-102 Osteoarthritis Multi-center Evaluation Trial), the Company's Phase 2b clinical trial designed to evaluate the safety and efficacy of Synavive (CRx-102) in subjects with symptomatic knee osteoarthritis (OA). While there was a trend in favor of Synavive, and an observed dose-response relationship, the combination did not demonstrate statistical significance compared to placebo for WOMAC question #1 measuring pain while walking on a flat surface (the primary endpoint), nor when compared to prednisolone alone. Analyses of the full dataset from the study remain ongoing. ...
Source: Law & Health Weekly (2008-10-25)
|
